Immediate Impact
40 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
Works of Thomas Van Cann being referenced
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center
2019
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Thomas Van Cann | 235 | 149 | 34 | 96 | 11 | 355 | |
| Hallie Zietz | 157 | 52 | 22 | 18 | 12 | 346 | |
| A. Visvikis | 250 | 119 | 10 | 35 | 18 | 379 | |
| E D Thomas | 80 | 57 | 74 | 28 | 12 | 373 | |
| P Ardissone | 233 | 186 | 29 | 15 | 9 | 397 | |
| Yulia Melenevsky | 80 | 96 | 9 | 63 | 13 | 367 | |
| A Dierick | 36 | 192 | 51 | 137 | 14 | 378 | |
| Jill L. Caudill | 187 | 121 | 28 | 86 | 14 | 381 | |
| Lea Latham | 155 | 170 | 8 | 20 | 17 | 389 | |
| Christine Muti | 117 | 113 | 132 | 43 | 18 | 389 | |
| George W. Changus | 150 | 150 | 53 | 102 | 9 | 371 |
All Works
Loading papers...